#### DAFTAR PUSTAKA

- Abdullah, M. R., Eswaramoorthi, V., Musa, R. M., Bisyri, A., & Musawi, H. (2016). The Effectiveness of Aerobic Exercises at difference Intensities of Managing Blood Pressure in Essential Hypertensive Information Technology Officers. 8(4), 483–486. https://doi.org/10.5530/jyp.2016.4.27
- Aileen, A., Kiu, W., Ying, S., Tze, D., Lee, F., Yin, D., Leung, P., Wing, J., Sit, H., Yu, H., & Taylor-piliae, R. E. (2018). Tai Chi Exercise is More Effective than Brisk Walking in Reducing Cardiovascular Disease Risk Factors among Adults with Hypertension: A Randomised Controlled Trial. *International Journal of Nursing Studies*. https://doi.org/10.1016/j.ijnurstu.2018.08.009
- American Heart Association. (2012). My Heart My Life, Warm Weather Fitness Guide. Dallas, Texas
- Black, J. M., & Jane Hokanson Hawks. (2014). *Keperawatan Medikal Bedah Manajemen Klinis untuk Hasil yang Diharapkan* (A. Susila, F. Ganiajri, L. P. Puji, & R. W. Arum Sari (eds.); Edisi 8 Bu). Salemba Medika.
- Börjesson, M., Onerup, A., Lundqvist, S., & Dahlöf, B. (2016). Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs. *British journal of sports medicine*, 50(6), 356–361. https://doi.org/10.1136/bjsports-2015-095786
- Celis-Morales CA, Gray S, Petermann F, Iliodromiti S, Welsh P, Lyall DM, Anderson J, Pellicori P, Mackay DF, Pell JP, Sattar N, Gill JMR. Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality. Med Sci Sports Exerc. 2019 Mar;51(3):472-480. doi: 10.1249/MSS.000000000001795. PMID: 30303933.
- Chan, A. W. K., Sit, J. W. H., Ying, S., Leung, D. Y. P., Lee, D. T. F., Wong, E. M. L., & Fung, L. C. W. (2016). Evaluation of the Effectiveness of Tai Chi versus Brisk Walking in Reducing Cardiovascular Risk Factors: Protocol for a Randomized Controlled Trial. 1–11. https://doi.org/10.3390/ijerph13070682
- Chan, A., Chair, S. Y., Lee, D., Leung, D., Sit, J., Cheng, H. Y., & Taylor-Piliae, R. E. (2018). Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial. *International journal of nursing studies*, 88, 44–52. https://doi.org/10.1016/j.ijnurstu.2018.08.009
- Chomistek, A. K., Henschel, B., Eliassen, A. H., Mukamal, K. J., & Rimm, E. B. (2016). Frequency, Type, and Volume of Leisure-Time Physical Activity and Risk of Coronary Heart Disease in Young Women. *Circulation*, 134(4), 290–299. https://doi.org/10.1161/CIRCULATIONAHA.116.021516
- Cohen, J., Korevaar D.A, & et al.. (2016). STARD 2015 quidelines for reporting diagnostic accuracy Studies. 1–17.
- Fritz, T., & Caidahl, K. (2013). Effects of Nordic walking on cardiovascular risk factors in overweight individuals with type 2 diabetes, impaired or normal glucose tolerance. July 2011, 25–32. https://doi.org/10.1002/dmrr

- Hall, J. E. (2011). Guyton And Hall: Textbook of Medical Physiology Twelfth Edition (12th ed.). Elsevier.
- Hariton, E., & Locascio, J. J. (2018). Randomised controlled trials—the gold standard for effectiveness research. *BJOG*, *125*(13). https://doi.org/10.1111/1471-0528.15199.
- He, L. I., Wei, W. ren, & Can, Z. (2018). Effects of 12-week brisk walking training on exercise blood pressure in elderly patients with essential hypertension: a pilot study. *Clinical and Experimental Hypertension*, 40(7), 673–679. https://doi.org/10.1080/10641963.2018.1425416
- Hegde, S. M., & Solomon, S. D. (2015). Influence of Physical Activity on Hypertension and Cardiac Structure and Function. *Current hypertension reports*, 17(10), 77. https://doi.org/10.1007/s11906-015-0588-3
- Higgins, J. P. T., Altman, D. G., C, P., Jüni, P., Moher, D., Oxman, A. D., Fellow, J. S., Vice, K. F. S., Weeks, L., & Sterne, J. A. C. (2011). RESEARCH METHODS & REPORTING:The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*, 1–9. https://doi.org/http://doi.org/10.1136/bmj.d5928
- http://navigatingeffectivetreatments.org.au/exploring\_systematic\_reviews\_parts\_full\_pag e.html. (2020). *Exploring systematic reviews*.
- https://lib.guides.umd.edu/. (2020). *Steps to conducting a systematic review*. University Libraries; University of Maryland.
- https://www.library.cornell.edu/. (2020). *A guide to evidence synthesis*. Cornell University Library.
- Instituto Joanna Briggs, J. (2020). JBI Reviewer Manual. March.
- Irwan, M. A., Mayumi, K., Kazuyo, K., & Eiichi, U. (2016). Development of the salt-reduction and ef fi cacy-maintenance program in Indonesia. *Nursing Health Science*. https://doi.org/10.1111/nhs.12305
- Joanna Briggs Institute. (2017). Checklist for Analytical Cross Sectional Studies.
- King, J. A., Wasse, L. K., Broom, D. R., & Stensel, D. J. (2010). Influence of brisk walking on appetite, energy intake, and plasma acylated ghrelin. *Medicine and Science in Sports and Exercise*, 42(3), 485–492. https://doi.org/10.1249/MSS.0b013e3181ba10c4
- Lee, L. L., Watson, M. C., Mulvaney, C. A., Tsai, C. C., & Lo, S. F. (2010). The effect of walking intervention on blood pressure control: A systematic review. *International Journal of Nursing Studies*, 47(12), 1545–1561. https://doi.org/10.1016/j.ijnurstu.2010.08.008
- Lejczak, A., Josiak, K., Węgrzynowska-Teodorczyk, K., Rudzińska, E., Jankowska, E. A., Banasiak, W., Piepoli, M. F., Woźniewski, M., & Ponikowski, P. (2016). Nordic walking may safely increase the intensity of exercise training in healthy subjects and in patients with chronic heart failure. Advances in Clinical and Experimental Medicine, 25(1), 145–149. https://doi.org/10.17219/acem/35094

- Maccgil, M. (2018). What is a randomized controlled trial? Medical News Today.
- Mancia, G., Fagard, R., Narkiewicz, K., Redán, J., Zanchetti, A., Böhm, M., ... & Galderisi, M. (2013). 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. *Journal of hypertension*, *31*(10), 1925-1938.
- Mandini, S., Conconi, F., Mori, E., Myers, J., Grazzi, G., & Mazzoni, G. (2018). Walking and hypertension: greater reductions in subjects with higher baseline systolic blood pressure following six months of guided walking. *PeerJ*, 6, e5471. https://doi.org/10.7717/peerj.5471
- McIver, V. J., Mattin, L., Evans, G. H., & Yau, A. M. W. (2019). The effect of brisk walking in the fasted versus fed state on metabolic responses, gastrointestinal function, and appetite in healthy men. *International Journal of Obesity*, *43*(9), 1691–1700. https://doi.org/10.1038/s41366-018-0215-x
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D. ., & Tugwell. P. (2009). Preferred reporting item for systematic reviews and meta-analysis. The PRISMA statement. *Plos Medicine*.
- Montero, D., Roche, E., & Martinez-Rodriguez, A. (2014). The impact of aerobic exercise training on arterial stiffness in pre- and hypertensive subjects: A systematic review and meta-analysis. *International Journal of Cardiology*, 173(3), 361–368. https://doi.org/10.1016/j.ijcard.2014.03.072
- Murtagh, E. M., Nichols, L., Mohammed, M. A., Holder, R., Nevill, A. M., & Murphy, M. H. (2015). The effect of walking on risk factors for cardiovascular disease: an updated systematic review and meta-analysis of randomised control trials. *Preventive medicine*, 72, 34–43. https://doi.org/10.1016/j.ypmed.2014.12.041
- NIH. (2000). Your guide to physical activity. *NIH Publication No.* 06-5714. http://www.nhlbi.nih.gov/health/resources/heart/obesity-guide-physical-active-html
- Patil, S. G., Aithala, M. R., & Das, K. K. (2015). Complementary Therapies in Medicine Effect of yoga on arterial stiffness in elderly subjects with increased pulse pressure: A randomized controlled study. *Complementary Therapies in Medicine*, 23(4), 562–569. https://doi.org/10.1016/j.ctim.2015.06.002
- Pescatello, L. S., MacDonald, H. V., Lamberti, L., & Johnson, B. T. (2015). Exercise for Hypertension: A Prescription Update Integrating Existing Recommendations with Emerging Research. *Current hypertension reports*, 17(11), 87. https://doi.org/10.1007/s11906-015-0600-y
- Riskesdas. (2018). Hasil Utama Riskesdas 2018.
- Rêgo, M. L., Cabral, D. A., Costa, E. C., & Fontes, E. B. (2019). Physical Exercise for Individuals with Hypertension: It Is Time to Emphasize its Benefits on the Brain and Cognition. *Clinical Medicine Insights. Cardiology*, 13, 1179546819839411. https://doi.org/10.1177/1179546819839411
- Roussel, M., Garnier, S., Lemoine, S., Gaubert, I., Charbonnier, L., Auneau, G., &

- Mauriège, P. (2009). Influence of a walking program on the metabolic risk profile of obese postmenopausal women. *Menopause*. https://doi.org/10.1097/gme.0b013e31818d4137
- Servantes, D. M., Pelcerman, A., Salvetti, X. M., Salles, A. F., De, P. F., Cezar, F., Salles, A. De, Lopes, C., Mello, M. T. De, Rodrigues, D., & Servantes, D. M. (2012). Effects of home-based exercise training for patients with chronic heart failure and sleep apnoea: a randomized comparison of two different programmes, . 45–57. https://doi.org/10.1177/0269215511403941
- Singh, S., Shankar, R., & Singh, G. P. (2017). Prevalence and Associated Risk Factors of Hypertension: A Cross-Sectional Study in Urban Varanasi. *International Journal of Hypertension*, 2017, 5491838. https://doi.org/10.1155/2017/5491838
- Sosner, P., Guiraud, T., Gremeaux, V., Arvisais, D., Herpin, D., & Bosquet, L. (2017). The ambulatory hypotensive effect of aerobic training: a reappraisal through a meta-analysis of selected moderators. *Scandinavian journal of medicine & science in sports*, 27(3), 327–341. https://doi.org/10.1111/sms.12661
- Stamatakis, E., Kelly, P., Strain, T., Murtagh, E. M., Ding, D., & Murphy, M. H. (2018). Self-rated walking pace and all-cause, cardiovascular disease and cancer mortality: individual participant pooled analysis of 50 225 walkers from 11 population British cohorts. *British journal of sports medicine*, *52*(12), 761–768. https://doi.org/10.1136/bjsports-2017-098677
- Subramanian, H., Soudarssanane, M. B., Jayalakshmy, R., Thiruselvakumar, D., & Navasakthi, D. (2011). Non pharmacological Interventions in Hypertension: A Community-based Cross-over Randomized Controlled Trial. 36(3). https://doi.org/10.4103/0970-0218.86519
- Sukarmin., Nurachmah E., & Gayatri D. (2013). Penurunan Tekanan Darah Pada Pasien Hipertensi Melalui *Brisk Walking Exercise*. *Jurnal Keperawatan Indonesia*, 16(1), 33-39. http://dx.doi.org/10.7454/jki.v16i1.17
- Sun, W., Wang, L., Song, Q., Gu, H., Ma, X., Zhang, C., & Mao, D. (2019). Effects of Tai Chi Chuan and Brisk walking exercise on balance ability in elderly women: A randomized controlled trial. *Motor Control*. https://doi.org/10.1123/mc.2017-0055
- Suri, H. (2017). Ethical Considerations of Conducting Systematic Reviews in Educational. Springer Fachmedien Wiesbaden. https://doi.org/10.1007/978-3-658-27602-7
- U.S. Departement of Helath and Human Service. (2018). *Physical Activity Guidelines for Americans, 2nd edition.* Washington, DC.
- Wager, E., & Wiffen, P. J. (2011). Ethical issues in preparing and publishing systematic reviews. 4, 130–134. https://doi.org/10.1111/j.1756-5391.2011.01122.x
- Welsh, C. E., Celis-morales, C. A., Ho, F. K., Brown, R., Mackay, D. F., Lyall, D. M., Anderson, J. J., Pell, J. P., Gill, J. M. R., Sattar, N., Welsh, P., & Gray, S. R. (2020).
  Grip Strength and Walking Pace and Cardiovascular Disease Risk Prediction in 406,834 UK Biobank Participants. *Mayo Clinic Proceedings*, 1–10. https://doi.org/10.1016/j.mayocp.2019.12.032

- Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Himmelfarb, C. D., ... & MacLaughlin, E. J. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 71(19), e127-e248.
- WHO. (2010). Global Recommendations on Physical Activity for Health. Publication of the World Health Organization.
- WHO. (2020). Cardiovascular Desease. World Health Organization.

# **LAMPIRAN**

Table 1| Cochrane Collaboration's tool for assessing risk of bias (adapted from Higgins and Altman13)

Bias domain	Source of bias	Support for judgment	Review authors' judgment (assess as low, unclear or high risk of bias)
Selection bias	Random sequence generation	Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups	Selection bias (biased allocation to interventions due to inadequate generation of a randomised sequence
	Allocation concealment	Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrolment	Selection bias (biased allocation to interventions due to inadequate concealment of allocations before assignment
Performance bias	Blinding of participants and personnel*	Describe all measures used, if any, to blind trial participants and researchers from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective	allocated interventions by participants and
Detection bias	Blinding of outcome assessment*	Describe all measures used, if any, to blind outcome assessment from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective	Detection bias due to knowledge of the allocated interventions by outcome assessment
Attrition bias	Incomplete outcome data*	Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition or exclusions where reported, and any reinclusions in analyses for the review	Attrition bias due to amount, nature, or handling of incomplete outcome data
Reporting bias	Selective reporting	State how selective outcome reporting was examined and what was found	Reporting bias due to selective outcome reporting
Other bias	Anything else, ideally prespecified	State any important concerns about bias not covered in the other domains in the tool	Bias due to problems not covered elsewhere

<sup>\*</sup>Assessments should be made for each main outcome or class of outcomes.





CASP Checklist: 11 questions to help you make sense of a Randomised Controlled Trial

How to use this appraisal tool: Three broad issues need to be considered when appraising a trial:

Are the results of the study valid? (Section A)
What are the results? (Section B)
Will the results help locally? (Section C)

The 11 questions on the following pages are designed to help you think about these issues systematically. The first three questions are screening questions and can be answered quickly. If the answer to both is "yes", it is worth proceeding with the remaining questions. There is some degree of overlap between the questions, you are asked to record a "yes", "no" or "can't tell" to most of the questions. A number of italicised prompts are given after each question. These are designed to remind you why the question is important. Record your reasons for your answers in the spaces provided.

**About:** These checklists were designed to be used as educational pedagogic tools, as part of a workshop setting, therefore we do not suggest a scoring system. The core CASP checklists (randomised controlled trial & systematic review) were based on JAMA 'Users' guides to the medical literature 1994 (adapted from Guyatt GH, Sackett DL, and Cook DJ), and piloted with health care practitioners.

For each new checklist, a group of experts were assembled to develop and pilot the checklist and the workshop format with which it would be used. Over the years overall adjustments have been made to the format, but a recent survey of checklist users reiterated that the basic format continues to be useful and appropriate.

Referending: we recommend using the Harvard style citation, i.e.: Critical Appraisal Skills
Programme (2018). CASP (insert name of checklist i.e. Randomised Controlled Trial) Checklist.
[online] Available at: URL. Accessed: Date Accessed.

©CASP this work is licensed under the Creative Commons Attribution – Non-Commercial-Share A like. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</a> www.casp-uk.net





CASP Checklist: 12 questions to help you make sense of a Cohort Study

How to use this appraisal tool: Three broad issues need to be considered when appraising a cohort study:

Are the results of the study valid? (Section A)
What are the results? (Section B)
Will the results help locally? (Section C)


The 12 questions on the following pages are designed to help you think about these issues systematically. The first two questions are screening questions and can be answered quickly. If the answer to both is "yes", it is worth proceeding with the remaining questions. There is some degree of overlap between the questions, you are asked to record a "yes", "no" or "can't tell" to most of the questions. A number of italicised prompts are given after each question. These are designed to remind you why the question is important. Record your reasons for your answers in the spaces provided.

**About:** These checklists were designed to be used as educational pedagogic tools, as part of a workshop setting, therefore we do not suggest a scoring system. The core CASP checklists (randomised controlled trial & systematic review) were based on JAMA 'Users' guides to the medical literature 1994 (adapted from Guyatt GH, Sackett DL, and Cook DJ), and piloted with health care practitioners.

For each new checklist, a group of experts were assembled to develop and pilot the checklist and the workshop format with which it would be used. Over the years overall adjustments have been made to the format, but a recent survey of checklist users reiterated that the basic format continues to be useful and appropriate.

Referencing: we recommend using the Harvard style citation, i.e.: Critical Appraisal Skills Programme (2018). CASP (insert name of checklist i.e. Cohort Study) Checklist. [online] Available at: URL. Accessed: Date Accessed.

©CASP this work is licensed under the Creative Commons Attribution – Non-Commercial-Share A like. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</a> www.casp-uk.net





(TITLE-ABS-KEY (hypertension) OR TITLE-ABS-KEY (high AND blood AND pressure) AND TITLE-ABS-KEY (brisk AND walking AND exercise) AND TITLE-ABS-KEY (blood AND pressure))


Search Sources Lists SciVal > UGM's Library Catalogue >


Create account


Sign in





Scopus














Section/topic	#	Checklist item	Reported on page #
TITLE	_		
Title 1 Identify the report as a systematic review, meta-analysis, or both.		Cover Line 2	
ABSTRACT			
		Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	
INTRODUCTION	W		
Rationale	Rationale 3 Describe the rationale for the review in the context of what is already known.		Page 3 Line 57-83
Objectives 4		Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
METHODS	•		
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, pregistration information including registration number.		Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Page 3 line 81-84
Eligibility criteria	Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.		Page 24 Line 12-17
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.		Page 24 line 20-31	
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.		Page 25 line 56-69	
Study selection	Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).		Page 26 line 74-80
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any process for obtaining and confirming data from investigators.		Page 27 line 97-101	

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Page 27 line 82-96
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).			
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistence (e.g., I <sup>2</sup> ) for each meta-analysis.			

Section/topic	# Checklist item		Reported on page #
Risk of bias across studies	Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).		
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS	'		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.		
Risk of bias across studies	Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15).		
Additional analysis	Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).		
DISCUSSION			
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).			
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	
Conclusions	Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.		
FUNDING			

Funding	27	escribe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the vstematic review.	

### From the Centre for Evidence-Based Medicine, Oxford

For the most up-to-date levels of evidence, see www.cebm.net/?o=1025

#### Therapy/Prevention/Etiology/Harm:


1a:	Systematic reviews (with homogeneity) of randomized controlled trials			
1b:	Individual randomized controlled trials (with narrow confidence interval)			
1c:	All or none randomized controlled trials			
2a:	Systematic reviews (with homogeneity) of cohort studies			
2b:	Individual cohort study or low quality randomized controlled trials (e.g. <80% follow-up)			
2c:	"Outcomes" Research; ecological studies			
3a:	Systematic review (with homogeneity) of case-control studies			
3b:	Individual case-control study			
4:	Case-series (and poor quality cohort and case-control studies)			
5:	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"			

Table 5
Grade Practice Recommendations\*

Grade	Descriptor	Qualifying Evidence	Implications for Practice
A	Strong recommendation	Level I evidence or consistent findings from multiple studies of levels II, III, or IV	Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present
В	Recommendation	Levels II, III, or IV evidence and findings are generally consistent	Generally, clinicians should follow a recommendation but should remain alert to new information and sensitive to patient preferences
С	Option	Levels II, III, or IV evidence, but findings are inconsistent	Clinicians should be flexible in their decision-making regarding appropriate practice, although they may set bounds on alternatives; patient preference should have a substantial influencing role
D	Option	Level V evidence: little or no systematic empirical evidence	Clinicians should consider all options in their decision making and be alert to new published evidence that clarifies the balance of benefit versus harm; patient preference should have a substantial influencing role

<sup>\*</sup>From the American Society of Plastic Surgeons. Evidence-based clinical practice guidelines. Available at: <a href="http://www.plasticsurgery.org/Medical\_Professionals/Health\_Policy\_and\_Advocacy/Health\_Policy\_Resources/Evidence-based\_GuidelinesPractice\_Parameters/Description\_and\_Development\_of\_Evidence-based\_Practice\_Guidelines/ASPS\_Grade\_Recommendation\_Scale.html. Accessed March 3, 2011</a>

## SCORE 10 year Fatal Cardiovascular Risk Evaluation in Canada



## Systematic coronary risk evaluation

